NEW SYSMEX TECHNOLOGY QUICKLY DETECTS CANCER FROM BLOOD
Wed. January 21, 2009; Posted: 10:55 PM
Larry Connors personally teaches Swing Trading College – Click here
TOKYO, Jan 22, 2009 (AsiaPulse via COMTEX) --
SSMXF |
Quote |
Chart |
News |
PowerRating -- Sysmex Corp. (TSE:6869) has developed technology that uses proprietary reagents to swiftly detect genetic changes associated with cells becoming cancerous.
The technology looks for a phenomenon known as methylation, in which a chemical structure called a methyl radical attaches to part of cytosine, one of the bases that makes up DNA.
Methylation happens when cells divide, and when unusual methylation occurs, the cell stops working normally and becomes cancerous.
Sysmex has developed a way to quickly determine whether genes in the blood have methylated.
Its approach shortens to two to three hours analysis that used to take one or two days.
If applied to the diagnosis of colon cancer, it could enable early detection of the cancer with high accuracy from blood samples alone.
The medical examination equipment manufacturer is engaging in joint research with German biotechnology company Epigenomics AG, which holds patents related to methylation patterns characteristic of colon cancer genes.
The aim is to combine this with the
new technology to create a screening system that can process large volumes of samples at high speed.
Linear Mode
